Long-acting diltiazem HCL for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 5, 2005, Pages 765-776

  Claas, Steven A ^a   Glasser, Stephen P ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Angina pectoris; Calcium channel blocker; Chronotherapy; Diltiazem HCL; Hypertension

Indexed keywords

ALDOSTERONE RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIZEM LA; CIMETIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG METABOLITE; ERYTHROMYCIN; INDINAVIR; LONG ACTING DRUG; MEVINOLIN; NIFEDIPINE; PHENOBARBITAL; PROPRANOLOL; RAMIPRIL; RIFAMPICIN; SERTINDOLE; VASODILATOR AGENT; VERAPAMIL;

ANGINA PECTORIS; AREA UNDER THE CURVE; ARTHRALGIA; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; ETHNIC DIFFERENCE; EXERCISE TOLERANCE; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; LIMB PAIN; MORTALITY; PERIPHERAL EDEMA; PHARMACOGENETICS; PRACTICE GUIDELINE; REVIEW; RISK REDUCTION; STABLE ANGINA PECTORIS; STRUCTURE ANALYSIS; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

ANGINA PECTORIS; CHRONIC DISEASE; CHRONOTHERAPY; DELAYED-ACTION PREPARATIONS; DILTIAZEM; HUMANS; HYPERTENSION;

EID: 19044389759     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.5.765     Document Type: Review

References (59)

1. KEARNEY PM, WHELTON M, REYNOLDS K, WHELTON PK, HE J: Worldwide prevalence of hypertension: a systematic review. J. Hypertens. (2004) 22(1):11-19.
2. WEBER MA, DRAYER JI, NAKAMURA DK, WYLE FA: The circadian blood pressure pattern in ambulatory normal subjects. Am. J. Cardiol. (1984) 54(1):115-119.
3. DRAYER JI, WEBER MA, NAKAMURA DK: Automated ambulatory blood pressure monitoring: a study in age-matched normotensive and hypertensive men. Am. Heart J. (1985) 109(6):1334-1338.
4. MULLER JE, LUDMER PL, WILLICH SN et al.: Circadian variation in the frequency of sudden cardiac death. Circulation (1987) 75(1):131-138.
5. MULLER JE, STONE PH, TURI ZG et al.: Circadian variation in the frequency of onset of acute myocardial infarction. N. Engl. J. Med. (1985) 313(21):1315-1322.
6. WILLICH SN, LINDERER T, WEGSCHEIDER K, LEIZOROVICZ A, ALAMERCERY I, SCHRODER R: Increased morning incidence of myocardial infarction in the ISAM Study: absence with prior beta-adrenergic blockade. ISAM Study Group. Circulation (1989) 80(4):853-858.
7. ROCCO MB, BARRY J, CAMPBELL S et al.: Circadian variation of transient myocardial ischaemia in patients with coronary artery disease. Circulation (1987) 75(2):395-400.
8. HAUSMANN D, LICHTLEN PR, NIKUTTA P, WENZLAFF P, DANIEL WG: Circadian variation of myocardial ischaemia in patients with stable coronary artery disease. Chronobiol. Int. (1991) 8(5):385-398.
9. MARLER JR, PRICE TR, CLARK GL et al.: Morning increase in onset of ischemic stroke. Stroke (1989) 20(4):473-476.
10. WILLICH SN, LEVY D, ROCCO MB, TOFLER GH, STONE PH, MULLER JE: Circadian variation in the incidence of sudden cardiac death in the Framingnam Heart Study population. Am. J. Cardiol. (1987) 60(10):801-806.
11. TOFLER GH, BREZINSKI D, SCHAFER AI et al.: Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N. Engl. J. Med. (1987) 316(24):1514-1518.
12. NADEMANEE K, INTARACHOT V, JOSEPHSON MA, SINGH BN: Circadian variation in occurrence of transient overt and silent myocardial ischaemia in chronic stable angina and comparison with Prinzmetal angina in men. Am. J. Cardiol. (1987) 60(7):494-498.
13. KARIO K, PICKERING TG, UMEDA Y et al.: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation (2003) 107(10):1401-1406.
14. KARIO K, PICKERING TG, HOSHIDE S et al.: Morning blood pressure surge and hypertensive cerebrovascular disease: role of the alpha adrenergic sympathetic nervous system. Am. J. Hypertens. (2004) 17(8):668-675.
15. KUMAGAI Y: Strategies against high blood pressure in the early morning. Clin. Exp. Hypertens. (2004) 26(2):107-118.
16. CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: Seventh report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42(6):1206-1252.
17. RAMSAY L, WILLIAMS B, JOHNSTON G et al.: Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J. Hum. Hypertens. (1999) 13(9):569-592.
18. CHALMERS J, MACMAHON S, MANCIA G et al.: 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines subcommittee of the World Health Organization. Clin. Exp. Hypertens. (1999) 21(5-6):1009-1060.
19. CUSHMAN WC, FORD CE, CUTLER JA et al.: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J. Clin. Hypertens. (2002) 4(6):393-404.
20. HANSSON L, ZANCHETTI A, CARRUTHERS SG et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 351(9118):1755-1762.
21. MATERSON BJ, REDA DJ, CUSHMAN WC et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. (1993) 328(13):914-921.
22. TIFFT CP: Joint National Committee VI: individualized versus indiscriminate therapy for hypertension. Curr. Hypertens. Rep. (2000) 2(3):243-246.
23. KOOPMANS RP, INSEL PA, MICHEL MC: Pharmacogenetics of hypertension treatment: a structured review. Pharmacogenetics (2003) 13(12):705-713.
24. ISKEDJIAN M, EINARSON TR, MACKEIGAN LD et al.: Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin. Ther. (2002) 24(2):302-316.
25. MUTSCHLER E, KNAUF H: Current status of sustained release formulations in the treatment of hypertension. An overview. Clin. Pharmacokinet. (1999) 37(Suppl. 1):1-6.
26. WHITE WB, LACOURCIERE Y, GANA T, PASCUAL MG, SMITH DH, ALBERT KS: Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. Am. Heart J. (2004) 148(4):628-634.
27. GLASSER SP: Circadian variations and chronotherapeutic implications for cardiovascular management: a focus on COER verapamil. Heart Dis. (1999) 1(4):226-232.
28. SMITH DH: Pharmacology of cardiovascular chronotherapeutic agents. Am. J. Hypertens. (2001) 14(9 Pt 2):296S-301S.
29. SICA D, FRISHMAN WH, MANOWITZ N: Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL), a new chronotherapeutic formulation. Heart Dis. (2003) 5(3):176-181.
30. HERMIDA RC, SMOLENSKY MH: Chronotherapy of hypertension. Curr. Opin. Nephrol. Hypertens. (2004) 13(5):501-505.
31. KURODA T, KARIO K, HOSHIDE S et al.: Effects of bedtime versus morning administration of the long-acting lipophilic angiotensin-converting enzyme inhibitor trandolapril on morning blood pressure in hypertensive patients. Hypertens. Res. (2004) 27(1):15-20.
32. + channels. Trends Pharmacol. Sci. (1998) 19(3):108-115.
33. POOL PE: Anomalies in the dosing of diltiazem. Clin. Cardiol. (2000) 23(1):18-23.
34. Biovail Pharmaceuticals I: Cardizem LA: Full Prescribing Information. In Bridgewater, NJ; (2004).
35. PALMA-GAMIZ JL: High blood pressure and calcium antagonism. Cardiology (1997) 88 Suppl. 1:39-46.
36. MESSERLI FH (Ed.), Cardiovascular Drug Therapy. 2nd edn. Philadelphia: Saunders: (1996).
37. BIGHLEY LD, DIMMITT DC, MCGRAW BF: Bioavailability if diltiazem hydrochloride formulations. Clincal Research. (1980) 28:587A.
38. ECHIZEN H, EICHELBAUM M: Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin. Pharmacokinet. (1986) 11(6):425-449.
39. BUCKLEY MM, GRANT SM, GOA KL, MCTAVISH D, SORKIN EM: Diltiazem. A reappraisal of its pharmacological properties and therapeutic use. Drugs (1990) 39(5):757-806.
40. HOGLUND P, NILSSON LG: Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. Ther. Drug Monit. (1989) 11(5):558-566.
41. YABANA H, NAGAO T, SATO M: Cardiovascular effects of the metabolites of diltiazem in dogs. J. Cardiovasc. Pharmacol. (1985) 7(1):152-157.
42. JOYAL M, PIEPER J, CREMER K, FELDMAN RL, PEPINE CJ: Pharmacodynamic aspects of intravenous diltiazem administration. Am. Heart J. (1986) 111(1):54-61.
43. POZET N, BRAZIER JL, AISSA AH et al.: Pharmacokinetics of diltiazem in severe renal failure. Eur. J. Clin. Pharmacol. (1983) 24(5):635-638.
44. SISTA S, LAI JC, ERADIRI O, ALBERT KS: Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration. J. Clin. Pharmacol. (2003) 43(10):1149-1157.
45. VALETTE H, APOIL E: Haemodynamic effects of diltiazem in healthy volunteers. Br. J. Clin. Pharmacol. (1980) 10(6):623-624.
46. TRIMARCO B, DELUCA N, RICCIARDELLI B et al.: Diltiazem in the treatment of mild or moderate essential hypertension. Comparison with metoprolol in a crossover double-blind trial. J. Clin. Pharmacol. (1984) 24(5-6):218-227.
47. OGAWA K, BAN M, ITO T et al.: Diltiazem for treatment of essential hypertension: a double-blind controlled study with reserpine. Clin. Ther. (1984) 6(6):844-853.
48. POOL PE, MASSIE BM, VENKATARAMAN K et al.: Diltiazem as monotherapy for systemic hypertension: a multicenter, randomized, placebo-controlled trial. Am. J. Cardiol. (1986) 57(4):212-217.
49. KOIWAYA Y, NAKAMURA M, MITSUTAKE A, TANAKA S, TAKESHITA A: Increased exercise tolerance after oral diltiazem, a calcium antagonist, in angina pectoris. Am. Heart J. (1981) 101(2):143-149.
50. POOL PE, SEAGREN SC, BONANNO JA, SALEL AF, DENNISH GW: The treatment of exercise-inducible chronic stable angina with diltiazem. Effect on treadmill exercise. Chest (19801 78(1 Suppl.):234-238.
51. STRAUSS WE, MCINTYRE KM, PARISI AF, SHAPIRO W: Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial. Am. J. Cardiol. (1982) 49(3):560-566.
52. WEIR MR: Diltiazem: ten years of clinical experience in the treatment of hypertension. J. Clin. Pharmacol. (1995) 35(3):220-232.
53. GINSBERG D, PAPPAS JE, ROFMAN BA et al.: Once-daily dosing of sustained-release diltiazem capsules in mild-to-moderate hypertension. J. Am. Osteopath. Assoc. (1988) 88(12):1489-1492.
54. MOOSER V, WAEBER B, NUSSBERGER J, BRUNNER HR: Antihypertensive effect of diltiazem administered once and twice daily. J. Hum. Hypertens. (1988) 2(4):257-260.
55. FELICETTA JV, SERFER HM, CUTLER NR et al.: A dose-response trial of once-daily diltiazem. Am. Heart J. (1992) 123(4 Pt 1):1022-1026.
56. MASSIE BM, DER E, HERMAN TS, TOPOLSKI P, PARK GD, STEWART WH: 24-hour efficacy of once-daily diltiazem in essential hypertension. Clin. Cardiol. (1992) 15(5):365-368.
57. GLASSER SP, NEUTEL JM, GANA TJ, ALBERT KS: Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension. Am. J. Hypertens. (2003) 16(1):51-58.
58. WRIGHT JT Jr. SICA DA, GANA TJ, BOHANNON K, PASCUAL LG, ALBERT KS: Antihypertensive efficacy of night time graded-release diltiazem versus morning amlodipine in African-Americans. Am. J. Hypertens. (2004) 17(9):734-742.
59. GLASSER SP, GANA TJ, PASCUAL LG, ALBERT KS: Efficacy and safety of a once-daily graded-release diltiazem HCl formulation dosed at bedtime (10PM) compared to placebo and to morning dosing (8AM) dosing in chronic stable angina pectoris. Am Heart J. (2005) 149(2): 290.e1-290.e9.